Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

The Role of Lipids in Immune Cell Function in SLE Patients

22. April 2020 aktualisiert von: University College, London

Understanding the Role Played by Serum and Membrane Lipids in Immune Cell Function in Patients With Systemic Lupus Erythematosus (SLE) and Healthy Donors

The overall aim of this project is to investigate the different types of immune cells found in the blood of patients with Systemic Lupus Erythematosus (SLE) and healthy donors. We know that the amount of fat on the surface of immune cells is an important factor controlling their behaviour. Immune cells from SLE patients are defective and this is associated with changes in the levels of fat on these cells. This project will investigate the level of fat in the blood and on immune cells from patients with SLE and age matched healthy controls, and measure how changes in the amount of fat can affect the way immune cells behave.

Studienübersicht

Detaillierte Beschreibung

Accelerated atherosclerosis is a serious complication of autoimmunity including patients with both adult and juvenile onset systemic lupus erythematosus (SLE). This suggests that defects in fat levels could contribute to disease pathogenesis. The immune system in patients with SLE does not work normally. In adult patients with SLE we know that many of the immune cells involved in protecting the body from infections or cancer are over-active and actually cause disease. In young people the immune system is still developing and very little is known about what goes wrong in patients that develop juvenile-onset SLE, whether this is the same as adult disease and whether the same treatments are relevant for this group of patients. This project aims to find out whether immune cells from SLE patients with adult-onset disease have the same defects as adult patients with juvenile-onset SLE. We know that an important factor that controls immune cell behaviour is the amount of fat that they have on their surface. We also know that a change in fat on immune cells from adult patients with SLE makes them defective. This project will investigate the level of fat in the blood and in immune cells from adult patients with juvenile-onset SLE and age matched healthy controls, and measure how changes in the amount of fat can affect the way immune cells behave. We will investigate how drugs that control fat levels can help to normalize the behaviour of immune cells from SLE patients.

Studientyp

Beobachtungs

Einschreibung (Voraussichtlich)

300

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 80 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

N/A

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Patients will be approached by the consultant rheumatologist when the patient is attending their normal outpatient clinic appointment.

Healthy donors will be approached in a similar way using information flyers, invitation letters and participant information sheets by a member of the research team.

Healthy volunteers from UCL staff will be made aware of the study and also asked to participate.

Beschreibung

Inclusion Criteria:

  • Diagnosis of SLE according to American College of Rheumatology revised criteria
  • Having given written informed consent prior to undertaking any study-related procedures.
  • Male and female patients between the ages of 18 and 80 years.

Patients who have met all the above inclusion criteria listed and healthy donors will be screened for the following exclusion criteria:

Exclusion Criteria:

  • Under any administrative or legal supervision.
  • Conditions/situations such as:
  • A concomitant autoimmune disease
  • Impossibility to meet specific protocol requirements (e.g. blood sampling).
  • Patient is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
  • Uncooperative or any condition that could make the patient potentially non-compliant to the study procedures.
  • Pregnant or breast-feeding women, currently or in the last three months prior to inclusion.
  • Patients who have been vaccinated in the last three months prior to inclusion.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Juvenile onset Systemic Lupus Erythematosus (SLE) patients
All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 11 and 21.
  • Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.
  • Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.
  • Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body.
Andere Namen:
  • Food Frequency Questionnaires (FFQs) and/or 24 hour diet recall questionnaires
  • Ultrasound Scan (USS)
  • GTN (glyceryl trinitrate) administration
Adult onset Systemic Lupus Erythematosus (SLE) patients
All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 24 and 80
  • Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.
  • Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.
  • Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body.
Andere Namen:
  • Food Frequency Questionnaires (FFQs) and/or 24 hour diet recall questionnaires
  • Ultrasound Scan (USS)
  • GTN (glyceryl trinitrate) administration
Matching healthy volunteers
Healthy volunteers, matched by age and gender, will be used as a control group
  • Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.
  • Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.
  • Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body.
Andere Namen:
  • Food Frequency Questionnaires (FFQs) and/or 24 hour diet recall questionnaires
  • Ultrasound Scan (USS)
  • GTN (glyceryl trinitrate) administration

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Collection of blood samples
Zeitfenster: 4 hours from point of sample collection
Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.
4 hours from point of sample collection
Completion of FFQ's and/or diet recall questionnaires
Zeitfenster: Same day as recruited to study.
FFQ's and/or diet recall questionnaires to assess dietary intake
Same day as recruited to study.
Cardiovascular Ultrasound scans (USS)
Zeitfenster: Within 2 months from recruitment.
USS of Intima Media Thickness (IMT), Flow Mediated Dilatation (FMD), Pulse Wave Velocity (PWV) and Laser Doppler Flowmetry measurement. As part of the procedure, sub lingual administration of GTN spray will be administered to measure FMD.
Within 2 months from recruitment.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: David Isenberg, Prof, UCL & University College London Hospitals NHS Foundation Trust

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

15. Februar 2016

Primärer Abschluss (Voraussichtlich)

31. August 2020

Studienabschluss (Voraussichtlich)

31. August 2020

Studienanmeldedaten

Zuerst eingereicht

22. April 2020

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

22. April 2020

Zuerst gepostet (Tatsächlich)

24. April 2020

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

24. April 2020

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

22. April 2020

Zuletzt verifiziert

1. April 2020

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Beschreibung des IPD-Plans

All participants are required to indicate in written consent if they agree to the use of any left over samples and associated data for future research use.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren